Rheumatoid arthritis

Showing results 41 - 50 of 100

Sorted by most recent

TitleAuthorDate

Individual patient data meta-analysis on continued use of glucocorticoids after their initiation as bridging therapy in patients with rheumatoid arthritis

Lotte van Ouwerkerk, Maarten Boers, Paul Emery, Pascal HP de Jong, Robert BM Landewé, Willem Lems, Josef S Smolen, Patrick Verschueren, Tom WJ Huizinga, Cornelia F Allaart, Sytske Anne Bergstra

16 December 2022

Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis

Daniel H Solomon, Jon T Giles, Katherine P Liao, Paul M Ridker, Pamela M Rist, Robert J Glynn, Rachel Broderick, Fengxin Lu, Meredith T Murray, Kathleen Vanni, Leah M Santacroce, Shady Abohashem, Philip M Robson, Zahi Fayad, Venkatesh ManiSee the full list of authors

30 November 2022

Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial

Jeffrey R Curtis, Kunihiro Yamaoka, Yi-Hsing Chen, Deepak L Bhatt, Levent M Gunay, Naonobu Sugiyama, Carol A Connell, Cunshan Wang, Joseph Wu, Sujatha Menon, Ivana Vranic, Juan J Gómez-Reino

5 December 2022

Tenderness and radiographic progression in rheumatoid arthritis and psoriatic arthritis

Irina Gessl, Claudia A Hana, Thomas Deimel, Martina Durechova, Miriam Hucke, Victoria Konzett, Mihaela Popescu, Paul Studenic, Gabriela Supp, Michael Zauner, Josef S Smolen, Daniel Aletaha, Peter Mandl

19 October 2022

Occupational inhalable agents constitute major risk factors for rheumatoid arthritis, particularly in the context of genetic predisposition and smoking

Bowen Tang, Qianwen Liu, Anna Ilar, Pernilla Wiebert, Sara Hägg, Leonid Padyukov, Lars Klareskog, Lars Alfredsson, Xia Jiang

6 December 2022

Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study

Lea Hoisnard, Laura Pina Vegas, Rosemay Dray-Spira, Alain Weill, Mahmoud Zureik, Emilie Sbidian

5 October 2022

Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis

Viktor Molander, Hannah Bower, Thomas Frisell, Benedicte Delcoigne, Daniela Di Giuseppe, Johan Askling, , The ARTIS study group, Gerd-Marie Alenius, Eva Baecklund, Katerina Chatzidionysiou, Nils Feltelius, Helena Forsblad-d’Elia, Alf Kastbom, Lars KlareskogSee the full list of authors

23 September 2022

PU.1 promotes development of rheumatoid arthritis via repressing FLT3 in macrophages and fibroblast-like synoviocytes

Jiajie Tu, Weile Chen, Yilong Fang, Dafei Han, Yizhao Chen, Haifeng Jiang, Xuewen Tan, Zhen Xu, Xuming Wu, Huihui Wang, Xiangling Zhu, Wenming Hong, Zhenbao Li, Chen Zhu, Xinming WangSee the full list of authors

5 October 2022

After JAK inhibitor failure: to cycle or to switch, that is the question – data from the JAK-pot collaboration of registries

Manuel Pombo-Suarez, Carlos Sanchez-Piedra, Juan Gómez-Reino, Kim Lauper, Denis Mongin, Florenzo Iannone, Karel Pavelka, Dan C Nordström, Nevsun Inanc, Catalin Codreanu, Kimme L Hyrich, Denis Choquette, Anja Strangfeld, Burkhard F Leeb, Ziga RotarSee the full list of authors

13 September 2022

Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

Christina Charles-Schoeman, Maya H Buch, Maxime Dougados, Deepak L Bhatt, Jon T Giles, Steven R Ytterberg, Gary G Koch, Ivana Vranic, Joseph Wu, Cunshan Wang, Kenneth Kwok, Sujatha Menon, Jose L Rivas, Arne Yndestad, Carol A ConnellSee the full list of authors

22 September 2022

Prev 1 2 3 456 7 8 9 10 Next